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We have studied the effects of inhibitors of the cGMP-
metabolizing phosphodiesterases PDE2 and PDE9 on
learning and memory.
Potent and selective inhibitors of phosphodiesterase 2
(PDE2) have long been elusive and most studies have
used EHNA, a micromolar compound which also affects
adenosine deaminase . Recently, we have developed and
characterized BAY 60-7550, a nanomolar inhibitor of
human PDE2A. Inhibition of PDE2 with BAY 60-7550 can
increase neuronal cGMP levels in response to a stimulus
of the NO/cGMP pathway in cell culture and slice models.
On a functional level, BAY 60-7550 was shown to increase
Long Term Potentiation (LTP), a physiological correlate of
learning and memory. In vivo, oral administration of BAY
60-7550 improves memory consolidation in rodent mod-
els of learning and memory.
While PDE2 is a dual acting PDE, that can act on cGMP as
well as on cAMP, PDE9 is a cGMP specific PDE. In contrast
o PDE2, PDE9 has a much lower Km and thus higher
affinity for its substrate. We have developed selective
inhibitors of PDE9A and studied their effects on learning
and memory. Similar to inhibitors of PDE2, these com-
pounds increase cGMP levels in vitro, improve LTP and
are active in several animal models of cognition. We there-
fore conclude that inhibition of both PDE2 and/or PDE9
is novel and effective paradigm to improve memory con-
solidation via the NO/cGMP pathway.
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